R&D drug firms back parallel EMA-HTA scientific advice but say it could be better
This article was originally published in Scrip
Executive Summary
There is strong support from R&D drug companies for the parallel scientific advice procedure that the European Medicines Agency and national health technology (HTA) bodies have been trialing since 2010.